TrialNeuro-oncology2010

Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide.

Mei-Yin C Polley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.